BioSpace News Archive

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced its participation in fireside chats at the following investor conferences.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a trial to investigate the ERK1/2 inhibitor ERAS-007 in combination with a KRAS G12C inhibitor in KRAS G12C-driven non-small cell lung cancer and colorectal cancer.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware.

Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022, at 1:00 p.m. ET in New York City.

Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, reported financial results and provided a business update for the quarter ended March 31, 2022.

Galera Therapeutics, Inc. announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. E.T.

OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced that the first patient has been dosed in the Phase 1b/2 Nautilus trial of OKI-179.

Taysha Gene Therapies, Inc. announced its participation in a fireside chat at the Jefferies Healthcare Conference, Goldman Sachs 43rd Annual Global Healthcare Conference, and JMP Securities Life Sciences Conference.

PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is being held in New York City, on June 15-16, 2022.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference.